About Elma Pharmaceuticals Private Limited
Data last updated: 21 February 2026
Elma Pharmaceuticals Private Limited is a private limited company based in Thrissur, Kerala, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 28 October 2004, the company has been in operation for over 22 years.
Registered with ROC Ernakulam under CIN U24232KL2004PTC017560.
Capital: an authorised share capital of ₹25 Lakh and a paid-up capital of ₹25 Lakh. It is led by directors including Panadan Poulose Shaju and Sukumar Amrutha.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Tc – 2/587/1 Laloor Road Elthuruth Po, Thrissur, Kerala, India – 680611.
As per the financials filed for FY 2025, the company reported a revenue of ₹14.46 Cr, a growth of 1% compared to the previous year.
The company has a workforce of approximately 29 employees as per the latest available data. Its group structure includes 2 subsidiaries.
As per MCA filings, the company has open charges of ₹2.83 Cr and satisfied charges of ₹2.78 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website elmapharma.com.
-
Email*****@*****.com
-
Telephone**************
-
Website
-
Social Media**************
-
Registered AddressTc – 2/587/1 Laloor Road Elthuruth Po, Thrissur, Kerala, India – 680611
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Elma Pharmaceuticals Private Limited
Elma Pharmaceuticals Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Elma Pharmaceuticals Private Limited
Elma Pharmaceuticals Private Limited is audited by VASU & SIVARAM for the financial year 2020. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| VASU & SIVARAM | blur-value | blur-value | blur-value |
Board of Directors of Elma Pharmaceuticals Private Limited
Elma Pharmaceuticals Private Limited is currently managed by 5 directors, with 6 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Panadan Poulose Shaju
Also directs:
Munus Pharmaceuticals Private Limited
|
Director | 26 Oct 2007 | 18 Years 8 Months | Current |
|
Sukumar Amrutha
Also directs:
Munus Pharmaceuticals Private Limited
|
Director | 26 Oct 2007 | 18 Years 8 Months | Current |
|
Sajimon Abraham
Also directs:
Munus Pharmaceuticals Private Limited
|
Director | 01 Nov 2008 | 17 Years 8 Months | Current |
|
Nadancheri Padikkal Padath Ajith
Also directs:
Munus Pharmaceuticals Private Limited
|
Director | 29 Oct 2004 | 21 Years 8 Months | Current |
|
Pallipuram Village Narayanan Sahasranaman
Also directs:
Munus Pharmaceuticals Private Limited
|
Managing Director | 20 Jul 2006 | 19 Years 11 Months | Current |
Financials of Elma Pharmaceuticals Private Limited FY 2025 filings available
Elma Pharmaceuticals Private Limited reported revenue of ₹14.46 Cr (up 1% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Elma Pharmaceuticals Private Limited
As of FY 2020, Elma Pharmaceuticals Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Elma Pharmaceuticals Private Limited
Elma Pharmaceuticals Private Limited has 2 subsidiary companies. This group structure data is as of FY 2020. The corporate group structure reflects Elma Pharmaceuticals Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Elma Bio Care Private Limited | U24290KL2020PTC061105 |
**.**%
|
| Munus Pharmaceuticals Private Limited | U24304KL2016PTC047341 |
**.**%
|
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Elma Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Dec 2023 | Others | ₹2.33 Cr | Open |
| 27 Aug 2020 | Others | ₹50 Lakh | Open |
| 11 Feb 2021 | Others | ₹2 Cr | Satisfied |
| 06 Dec 2014 | The South Indian Bank Limited | ₹28 Lakh | Satisfied |
| 05 Dec 2014 | The South Indian Bank Limited | ₹42 Lakh | Satisfied |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Elma Pharmaceuticals Private Limited
Elma Pharmaceuticals Private Limited has a workforce of 29 employees as of Apr 05, 2024.
Employee Count & EPFO Data of Elma Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Elma Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Elma Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Elma Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Elma Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Elma Pharmaceuticals Private Limited
MSME Payment Delays by Elma Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Elma Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Elma Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Elma Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Elma Pharmaceuticals Private Limited
MCA Filings & Documents of Elma Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Elma Pharmaceuticals Private Limited
Frequently Asked Questions about Elma Pharmaceuticals Private Limited
Elma Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in Thrissur, Kerala, India. It was incorporated on 28 October 2004 (22+ years old) and is registered under CIN U24232KL2004PTC017560. The company has 29 employees.
Elma Pharmaceuticals Private Limited reported revenue of ₹14.46 Cr for FY 2025 (up 1.00% YoY).
The current directors of Elma Pharmaceuticals Private Limited are:
The primary industry of Elma Pharmaceuticals Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Elma Pharmaceuticals Private Limited can be reached at the registered office: Tc – 25871 Laloor Road Elthuruth Po, Thrissur, Kerala, India – 680611, or through the website elmapharma.com.
The authorised capital is ₹25 Lakh, and the paid-up capital is ₹25 Lakh.